# TNFRSF11B

## Overview
TNFRSF11B is a gene that encodes the protein osteoprotegerin (OPG), a member of the tumor necrosis factor receptor superfamily. OPG functions primarily as a soluble decoy receptor, playing a critical role in bone metabolism by inhibiting the interaction between receptor activator of nuclear factor kappa-B ligand (RANKL) and its receptor RANK on osteoclast precursor cells. This inhibition is crucial for regulating osteoclastogenesis, thereby maintaining bone density and preventing excessive bone resorption. Beyond its role in bone homeostasis, OPG is involved in immune regulation and vascular health, as it is expressed in various tissues, including bone, thymus, and intestinal mucosa. The balance between RANKL and OPG is essential for normal skeletal integrity and has implications for diseases such as juvenile Paget's disease and idiopathic hyperphosphatasia, which are linked to mutations in the TNFRSF11B gene (Bucay1998osteoprotegerindeficient; Chong2003Idiopathic; Tsukasaki2020OPG).

## Structure
TNFRSF11B, also known as osteoprotegerin (OPG), is a glycoprotein characterized by a complex molecular structure. The primary structure of TNFRSF11B includes a signal peptide and multiple cysteine-rich domains, which are crucial for its function as a decoy receptor for RANKL, thereby inhibiting osteoclastogenesis. The secondary structure of the protein features both beta-sheets and alpha-helices, contributing to its stability and functional conformation.

In terms of tertiary structure, TNFRSF11B is stabilized by disulfide bonds, which are essential for maintaining its three-dimensional shape and ensuring proper function. The quaternary structure of TNFRSF11B involves the formation of homodimers, which is a common structural feature that enhances its biological activity.

Post-translational modifications, such as glycosylation, play a significant role in the protein's stability and function. These modifications can affect the protein's interaction with other molecules and its overall stability. Additionally, splice variants of TNFRSF11B may exist, potentially influencing its function and stability, although specific details on these variants are not provided in the context. This structural complexity allows TNFRSF11B to effectively perform its role in bone metabolism and immune regulation.

## Function
The TNFRSF11B gene encodes osteoprotegerin (OPG), a crucial protein in bone remodeling and immune system regulation. OPG functions as a soluble decoy receptor that binds to the receptor activator of nuclear factor kappa-B ligand (RANKL), preventing its interaction with the receptor RANK on osteoclast precursor cells. This inhibition is essential for regulating osteoclastogenesis, the process by which osteoclasts, the cells responsible for bone resorption, are formed. By blocking RANKL-RANK interactions, OPG reduces osteoclast differentiation and activity, thereby maintaining bone density and preventing excessive bone loss (Chong2003Idiopathic; Mizuno1998Severe).

In healthy human cells, OPG is primarily produced by osteoblastic cells in bone tissue, where it plays a critical role in maintaining bone homeostasis. It is also expressed in other tissues, including the thymus and intestinal mucosa, where it contributes to immune system regulation and intestinal homeostasis (Tsukasaki2020OPG). OPG's role extends to vascular health, as it helps prevent arterial calcification, linking bone and vascular health (Bucay1998osteoprotegerindeficient). The balance between RANKL and OPG is vital for normal bone remodeling and overall skeletal integrity (Mitton‐Fitzgerald2021Effects).

## Clinical Significance
Mutations in the TNFRSF11B gene, which encodes osteoprotegerin (OPG), are associated with several bone disorders. Idiopathic hyperphosphatasia (IH) is a rare congenital bone disease linked to mutations in TNFRSF11B. These mutations disrupt the gene's ability to bind RANKL, leading to high bone turnover and varying severities of the disease phenotype. Severe forms of IH are associated with missense mutations in cysteine residues or large deletions, while milder forms are linked to non-cysteine missense mutations (Chong2003Idiopathic).

Juvenile Paget's disease is another condition associated with TNFRSF11B mutations. Patients with this disease have been found to have homozygous deletions of the TNFRSF11B gene, resulting in osteoprotegerin deficiency. This deficiency leads to rapid bone remodeling, osteopenia, and skeletal deformities (Whyte2002Osteoprotegerin).

Alterations in TNFRSF11B expression levels are also implicated in gastric cancer. High expression of TNFRSF11B is associated with poor prognosis, promoting cell proliferation and inhibiting apoptosis. It activates the Wnt/β-catenin signaling pathway, contributing to aggressive cancer phenotypes (Luan2020TNFRSF11B). Additionally, polymorphisms in TNFRSF11B may influence the risk of developing Paget's disease of bone, particularly in women, suggesting a sex-specific genetic influence (Beyens2007Identification).

## Interactions
TNFRSF11B, also known as osteoprotegerin (OPG), is a decoy receptor that interacts with several proteins, playing a significant role in bone metabolism and immune regulation. OPG primarily binds to RANKL (Receptor Activator of Nuclear Factor Kappa-Β Ligand), inhibiting its interaction with RANK, which is essential for osteoclast differentiation and bone resorption (Nelson2012RANKL). This interaction is characterized by OPG's ability to occupy two RANKL binding sites simultaneously, facilitated by a sharp bend around its hinge region, resulting in high-affinity binding (Nelson2012RANKL).

OPG also interacts with TRAIL (TNF-related apoptosis-inducing ligand), acting as a soluble decoy receptor that inhibits TRAIL-induced apoptosis. This interaction involves the formation of a heteromeric complex with the agonistic receptor TRAILR2/DR5, reducing caspase-8 activation and apoptosis (Minchenko2016The). The competitive binding of OPG to TRAIL may have implications for therapeutic treatments, as it can inhibit apoptosis in cancer cells (Luan2020TNFRSF11B).

Mutations in the TNFRSF11B gene can disrupt these interactions, leading to diseases such as juvenile Paget's disease and idiopathic hyperphosphatasia, which are characterized by altered bone remodeling and resorption (Chong2003Idiopathic; Nelson2012RANKL).


## References


[1. (Mitton‐Fitzgerald2021Effects) Elizabeth Mitton‐Fitzgerald, Claudia M. Gohr, Charlene J. Williams, Amaryllis Ortiz, Gabriel Mbalaviele, and Ann K. Rosenthal. Effects of the tnfrsf11b mutation associated with calcium pyrophosphate deposition disease in osteoclastogenesis in a murine model. Arthritis &amp; Rheumatology, 73(8):1543–1549, June 2021. URL: http://dx.doi.org/10.1002/art.41678, doi:10.1002/art.41678. This article has 10 citations.](https://doi.org/10.1002/art.41678)

[2. (Minchenko2016The) O. H. Minchenko, D. O. Tsymbal, D. O. Minchenko, and О. O. Ratushna. The role of the tnf receptors and apoptosis inducing ligands in tumor growth. The Ukrainian Biochemical Journal, 88(5):18–37, October 2016. URL: http://dx.doi.org/10.15407/ubj88.05.018, doi:10.15407/ubj88.05.018. This article has 8 citations.](https://doi.org/10.15407/ubj88.05.018)

[3. (Nelson2012RANKL) Christopher A. Nelson, Julia T. Warren, Michael W.-H. Wang, Steven L. Teitelbaum, and Daved H. Fremont. Rankl employs distinct binding modes to engage rank and the osteoprotegerin decoy receptor. Structure, 20(11):1971–1982, November 2012. URL: http://dx.doi.org/10.1016/j.str.2012.08.030, doi:10.1016/j.str.2012.08.030. This article has 91 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.str.2012.08.030)

[4. (Whyte2002Osteoprotegerin) Michael P. Whyte, Sara E. Obrecht, Patrick M. Finnegan, Jonathan L. Jones, Michelle N. Podgornik, William H. McAlister, and Steven Mumm. Osteoprotegerin deficiency and juvenile paget’s disease. New England Journal of Medicine, 347(3):175–184, July 2002. URL: http://dx.doi.org/10.1056/nejmoa013096, doi:10.1056/nejmoa013096. This article has 344 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1056/nejmoa013096)

[5. (Bucay1998osteoprotegerindeficient) N. Bucay, I. Sarosi, C. R. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H. L. Tan, W. Xu, D. L. Lacey, W. J. Boyle, and W. S. Simonet. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes &amp; Development, 12(9):1260–1268, May 1998. URL: http://dx.doi.org/10.1101/gad.12.9.1260, doi:10.1101/gad.12.9.1260. This article has 1888 citations.](https://doi.org/10.1101/gad.12.9.1260)

[6. (Luan2020TNFRSF11B) Fengming Luan, Xiaomei Li, Xiaojing Cheng, Longtao Huangfu, Jing Han, Ting Guo, Hong Du, Xianzi Wen, and Jiafu Ji. Tnfrsf11b activates wnt/β-catenin signaling and promotes gastric cancer progression. International Journal of Biological Sciences, 16(11):1956–1971, 2020. URL: http://dx.doi.org/10.7150/ijbs.43630, doi:10.7150/ijbs.43630. This article has 39 citations and is from a peer-reviewed journal.](https://doi.org/10.7150/ijbs.43630)

[7. (Beyens2007Identification) Greet Beyens, Anna Daroszewska, Fenna de Freitas, Erik Fransen, Filip Vanhoenacker, Leon Verbruggen, Hans-Georg Zmierczak, René Westhovens, Jan Van Offel, Stuart H Ralston, Jean-Pierre Devogelaer, and Wim Van Hul. Identification of sex-specific associations between polymorphisms of the osteoprotegerin gene, tnfrsf11b, and paget’s disease of bone. Journal of Bone and Mineral Research, 22(7):1062–1071, July 2007. URL: http://dx.doi.org/10.1359/jbmr.070333, doi:10.1359/jbmr.070333. This article has 55 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1359/jbmr.070333)

[8. (Chong2003Idiopathic) Belinda Chong, Madhuri Hegde, Matthew Fawkner, Scott Simonet, Hamilton Cassinelli, Mahmut Coker, John Kanis, Joerg Seidel, Cristina Tau, Beyhan Tüysüz, Bilgin Yüksel, Donald Love, and Tim Cundy. Idiopathic hyperphosphatasia and tnfrsf11b mutations: relationships between phenotype and genotype. Journal of Bone and Mineral Research, 18(12):2095–2104, December 2003. URL: http://dx.doi.org/10.1359/jbmr.2003.18.12.2095, doi:10.1359/jbmr.2003.18.12.2095. This article has 99 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1359/jbmr.2003.18.12.2095)

[9. (Mizuno1998Severe) Atsuko Mizuno, Norio Amizuka, Kazuharu Irie, Akihiko Murakami, Nobuaki Fujise, Takeshi Kanno, Yasushi Sato, Nobuaki Nakagawa, Hisataka Yasuda, Shin-ichi Mochizuki, Takashi Gomibuchi, Kazuki Yano, Nobuyuki Shima, Naohiro Washida, Eisuke Tsuda, Tomonori Morinaga, Kanji Higashio, and Hidehiro Ozawa. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochemical and Biophysical Research Communications, 247(3):610–615, June 1998. URL: http://dx.doi.org/10.1006/bbrc.1998.8697, doi:10.1006/bbrc.1998.8697. This article has 611 citations and is from a peer-reviewed journal.](https://doi.org/10.1006/bbrc.1998.8697)

[10. (Tsukasaki2020OPG) Masayuki Tsukasaki, Tatsuo Asano, Ryunosuke Muro, Nam Cong-Nhat Huynh, Noriko Komatsu, Kazuo Okamoto, Kenta Nakano, Tadashi Okamura, Takeshi Nitta, and Hiroshi Takayanagi. Opg production matters where it happened. Cell Reports, 32(10):108124, September 2020. URL: http://dx.doi.org/10.1016/j.celrep.2020.108124, doi:10.1016/j.celrep.2020.108124. This article has 66 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.celrep.2020.108124)